Morgan Stanley's decision to maintain an Equal-Weight rating on Ameren indicates a neutral outlook for the stock. The lowered price target from $92 to $90 may have a minor negative impact on investor sentiment, but the overall impact on the stock price is expected to be neutral in the short term.